A new generation of daily tablets is reshaping the race for obesity treatments.
Oral versions of GLP-1 drugs could bring weight-loss therapy to far more people.
Analysts expect the market to approach $200bn by the early 2030s.
Novo Nordisk has launched the first oral Wegovy in the US.
Early demand has been strong, with rapid prescription growth.
Patients say pills are easier to use, cheaper and do not require refrigeration.
Many users switch because of insurance costs or needle fatigue.
Daily dosing provides steadier appetite control for some people.
However, injections still produce greater weight loss in studies.
Eli Lilly is preparing a rival pill, intensifying competition.
Both companies hope tablets will attract new patients with milder obesity.
Expanded insurance coverage in the US will further boost uptake.
High prices, side-effects and long-term weight regain remain concerns.
Health systems are watching costs closely.
Even so, growing obesity rates and easier drug formats are driving demand.
